WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 5 fonti

Wegovy and Mounjaro obesity drugs ‘do not improve quality of life’ | The National

BMJ study of almost 100,000 patients finds increased weight loss was associated with greater harms

Raccontata dathenationalnews.commirror.co.ukindependent.co.ukdailymail.comeuronews.com

Confronto fonti

5 prospettive sulla stessa storia
AI · summaries
thenationalnews.comStai leggendo21 h fa

Wegovy and Mounjaro obesity drugs ‘do not improve quality of life’ | The National

BMJ study of almost 100,000 patients finds increased weight loss was associated with greater harms

originale
independent.co.uk14 h fa

Weight loss drugs found to ‘not improve quality of life’

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be…

Leggi questa versione → originale
euronews.com14 h fa

Obesity drugs cut weight but don’t improve life quality, study finds

Obesity drugs are growing in popularity worldwide, but a new study has found that, beyond the weight-loss results, most of these medications do not bring broader quality-of-life benefits after one year of use.

Leggi questa versione → originale
dailymail.com21 h fa

Wegovy 'is just as good as fat jabs when it comes to weight loss'

A review of existing data on weight-loss medicines concluded that while people lose weight, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life.

Leggi questa versione → originale
mirror.co.uk21 h fa

Weight loss medicines ‘do not increase quality of life’, study shows

Weight loss injections and pills cause ‘no meaningful improvement’ in quality of life as the more pounds people shed the higher risk of side effects and muscle wastage

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 9 luglio 2026·thenationalnews.com

    Wegovy and Mounjaro obesity drugs ‘do not improve quality of life’ | The National

    BMJ study of almost 100,000 patients finds increased weight loss was associated with greater harms

  2. giovedì 9 luglio 2026·mirror.co.uk

    Weight loss medicines ‘do not increase quality of life’, study shows

    Weight loss injections and pills cause ‘no meaningful improvement’ in quality of life as the more pounds people shed the higher risk of side effects and muscle wastage

  3. giovedì 9 luglio 2026·independent.co.uk

    Study finds most weight loss drugs including Wegovy ‘do not improve quality of life’

    Wegovy pills found to have less positive impact on heart health than injectable counterparts

  4. giovedì 9 luglio 2026·dailymail.com

    Wegovy 'is just as good as fat jabs when it comes to weight loss'

    A review of existing data on weight-loss medicines concluded that while people lose weight, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of…

  5. giovedì 9 luglio 2026·euronews.com

    Obesity drugs cut weight but don’t improve life quality, study finds

    Obesity drugs are growing in popularity worldwide, but a new study has found that, beyond the weight-loss results, most of these medications do not bring broader quality-of-life…

  6. giovedì 9 luglio 2026·independent.co.uk

    Weight loss drugs found to ‘not improve quality of life’

    Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…